<?xml version="1.0" encoding="UTF-8"?>
<p id="p1110">Current absence of antiviral for dengue has triggered much research in the field of dengue drug discovery and many hypotheses that treatment with an effective antiviral within 48Â hours of the onset of the disease may lead to rapid reduction in viral load and limit the development of severe dengue. It may also lead to reduced disease morbidity in DF patients as well as reduced transmission. Few experiments revealed that levels of proinflammatory cytokines and the extent of splenomegaly were also reduced with the drug treatment. Human clinical trials in patients with acute dengue have been conducted with chloroquine (
 <xref rid="bib307" ref-type="bibr">Tricou et al., 2010</xref>) and balapiravir (
 <xref rid="bib240" ref-type="bibr">Nguyen et al., 2013</xref>). 
</p>
